ArticleCureus2026
Melkersson-Rosenthal Syndrome: A Case Treated With Infliximab.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melkersson-Rosenthal Syndrome (MRS) is a rare disorder of unknown etiology, clinically characterized by a triad of recurrent orofacial swelling with facial palsy and a fissured tongue. Diagnosis is based on physical findings and history, with a biopsy potentially needed for histological confirmation. We present a case of a 40-year-old woman, referred by her stomatologist to our Department of Internal Medicine for granulomatous cheilitis. After excluding other etiologies and in the presence of a compatible biopsy, the diagnosis of MRS was made. There is no standardized treatment for MRS, and most therapeutic decisions are based on isolated case reports and small case series; management is, therefore, individualized according to patient response. In the current reported case, after several different therapeutic regimens had failed, the patient was treated with infliximab and has been improving progressively thereafter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.